ArticleBMC pediatrics2026
A single-center retrospective study of a decade-long experience in managing pediatric lymphatic malformation.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
objectivesLymphatic malformations (LMs) are rare pediatric conditions that present variable symptoms depending on lesion size and anatomical location, necessitating diverse treatment approaches. This study aims to characterize the clinical features and prognosis of LMs across different anatomical sites and to compare the therapeutic efficacy of various treatment modalities. MATERIALS AND
methodsA retrospective analysis was performed on 478 pediatric patients diagnosed with LMs at Beijing Children's Hospital between January 2014 and December 2024. Data regarding patient demographics, clinical characteristics, treatment modalities, and therapeutic outcomes were extracted and analyzed.
resultsThe head and neck region was the most involved site (45.0%). Macrocysts were predominantly located in the pelvic/abdominal, mixed cysts in the head and neck, and microcysts in the trunk/extremities (p < 0.01). The macrocystic subtype demonstrated the most favorable response across all therapeutic modalities (p < 0.05). Furthermore, no statistically significant difference in effective rates was observed between surgery and sclerotherapy.
conclusionsSubtype distribution demonstrated distinct anatomic predilections. Surgery and sclerotherapy both achieve high effective rates when selected according to appropriate clinical indications. Macrocystic LMs appeared to have the best therapeutic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.